You are here

Alzheimer’s Drug Trial Halted Because of Liver Problems

Research continues on beta secretase inhibitor (June 13)

A phase II trial of Y2886721, an investigational Alzheimer’s disease (AD) drug, has been terminated because of abnormal liver biochemical tests. The beta secretase (BACE) inhibitor was being investigated as a once-daily treatment for its potential to slow the progression of AD.

In a press announcement, the drug’s developer (Eli Lilly) stated that it believes the study’s negative findings were not related to the BACE mechanism. The company continues to be interested in developing BACE inhibitors for patients with AD.

LY2886721 is a chemical entity that blocks the formation of Aß resulting from the cleavage of amyloid precursor protein (APP).

The total number of new cases of dementia each year worldwide is nearly 7.7 million, which is the equivalent of one new case every 4 seconds. According to different estimates, between 2% and 10% of all cases of dementia start before the age of 65. Advancing age is the strongest risk factor for AD, with age-specific prevalence nearly doubling every 5 years beyond the age of 65. The total estimated worldwide cost of dementia was $604 billion in 2010.

Source: Eli Lilly; June 13, 2013.

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
First Medicines for Adults With Wild-type or Hereditary ATTR-CM